Skip to main content
ARS Home » Plains Area » Manhattan, Kansas » Center for Grain and Animal Health Research » ABADRU » Research » Publications at this Location » Publication #347182

Research Project: Orbivirus Pathogenesis, Epidemiology, and Control Measures

Location: Arthropod-borne Animal Diseases Research

Title: Disa vaccines for Bluetongue: A novel vaccine approach for insect-borne diseases

item VAN RIJN, PIET - University Of Wageningen
item BOONSTRA, JAN - University Of Wageningen
item DAUS, FRANZ - University Of Wageningen
item FEENSTRA, FEMKE - University Of Wageningen
item VAN GENNIP, RENE G.P. - University Of Wageningen
item MARIS-VELDHUIS, MIEKE - University Of Wageningen
item TACKEN, MIRRIAM G.J. - University Of Wageningen
item VAN DE WATER, SANDRA G.P. - University Of Wageningen
item Drolet, Barbara

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 8/7/2017
Publication Date: 9/19/2017
Citation: Van Rijn, P.A., Boonstra, J., Daus, F.J., Feenstra, F., Van Gennip, R., Maris-Veldhuis, M.A., Tacken, M., Van De Water, S., Potgieter, C., Drolet, B.S. 2017. DISA vaccines for Bluetongue: A Novel Vaccine Approach for Insect-Borne Diseases. Meeting Abstract. 1/1.

Interpretive Summary:

Technical Abstract: Bluetongue virus (BTV) lacking functional NS3/NS3a protein is named Disabled Infectious Single Animal (DISA) vaccine. The BT DISA vaccine platform is broadly applied by exchange of serotype specific proteins. BT DISA vaccines are produced in standard cell lines in established production facilities, and are not pathogenic nor virulent. BT DISA vaccination induces rapid, long lasting, and serotype specific protection. BT DISA vaccination only requires a low vaccine dose, and is flexible with regard to the route of vaccination.BT DISA vaccines are virologically and serologically DIVA compatible. BT DISA vaccines are not transmitted by lack of viremia in the host and by lack of propagation in the insect vector (DISA principle).